About US
Contact us
-
Impax whacks jobs to try to right itself after Rytary delays cost it GSK dealImpax Laboratories' ($IPXL) is cutting roughly 10% of its workforce, or 110 jobs, after problems at its manufacturing plant in California cost it FDA consideration of a drug application and then a par2013/6/6
-
India's Cadila scouts Big Pharma partners to launch new diabetes drug abroadCadila Healthcarewants to partner with Big Pharma. The Indian drugmaker won domestic approval for a brand-new drug fordiabetics, Lipaglyn, that it's prepared to launch in its own country later this ye2013/6/6
-
3rd Excipient Festival China & Forum of International Drug Preparation & Pharmaceutical Excipient Development 2013’ has successfully come to an end3rd Excipient Festival China which hosted by CPEC, organized by PHEXCOM and co-organized by CPIA, Sichuan Pharmaceutical Association and West China School of Pharmacy Sichuan University has completed2013/6/5
-
Older drugs aren't just cheaper, they're better, study saysCritics contend that statistics blur important pharma breakthroughs Generic drugs already have cost on their side when competing with pricey brands. But according to a new study inHealth Affairs, old2013/6/5
-
Limited track-and-trace moves forward in U.S.The U.S. House of Representatives has advanced one step closer to delaying the tracking of individual drug units. A House bill passed today would direct theFDAto create national standards for monitori2013/6/5
-
GSK's kidney cancer drug delays ovarian cancer relapseGlaxoSmithKline's maintenance therapy Votrient delayed disease progression in patients with advanced epithelial ovarian cancer by an average of 5.6 months following front-line chemotherapy. In a Phas2013/6/4
-
Lilly blockbuster Alimta burned by more disappointing newsThere is bad news out of ASCO for Eli Lilly's ($LLY) Alimta, its blockbuster lung cancer drug that is already under a patent assault by Teva Pharmaceutical Industries ($TEVA). Lilly today announced t2013/6/4
-
UCB sells off Rochester plant; buyer to keep 300 workersThe Belgian drugmaker UCB agreed to sell a plant in Rochester, NY, as it restructures its manufacturing operations to rely more on contract drugmakers. The sale to France-based Unither includes a 6-ye2013/5/30
-
Consumer Reports warns against fast-growing use of testosterone drugsConsumer Reports has weighed in on the rising use of testosterone drugs, which added some $2 billion to drugmakers' coffers last year. If patients listen to the magazine, pharma companies could watch2013/5/30
-
When is it fair to slap a 'pay for delay' label on a patent settlement?Are antitrust regulators unfairly targeting Big Pharma's patent settlements? As the debate rages on--and continues to spread--more experts and pharma execs are pushing back, the Financial Times repor2013/5/29